ArticleWorld journal of gastroenterology2002
P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.
Article in World journal of gastroenterology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.European journal of cancer (Oxford, England : 1990) · 2012Pooled it
- p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC: one-year follow-up.World journal of gastroenterology · 2011Trial
- Pathological prognostic factors for post-resection survival in patients with hepatocellular carcinoma associated with non-alcoholic fatty liver disease.Translational cancer research · 2021Article
- Risk Categorization with Different Grades of Cervical Pre-Neoplastic Lesions - High Risk HPV Associations and Expression of p53 and RARβAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Precision medicine: In need of guidance and surveillance.World journal of gastroenterology · 2017Article
- Genome-wide association study identified PLCE1- rs2797992 and EGFR- rs6950826 were associated with TP53 expression in the HBV-related hepatocellular carcinoma of Chinese patients in Guangxi.American journal of translational research · 2016Article
- Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.Hepatobiliary surgery and nutrition · 2014Article
- Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.International journal of hepatology · 2013Article
- Hepatocellular tumors: immunohistochemical analyses for classification and prognostication.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2011Article
- Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran.World journal of gastroenterology · 2007Article
- Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.Journal of cancer research and clinical oncology · 2004Review
- A decade's studies on metastasis of hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2004Review
- Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.World journal of gastroenterology · 2003Article
- Biological characteristics of HCC by ultrasound-guided aspiration biopsy and its clinical application.World journal of gastroenterology · 2003Article
- Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity.World journal of gastroenterology · 2003Article
- Codon 249 mutation in exon 7 of p53 gene in plasma DNA: maybe a new early diagnostic marker of hepatocellular carcinoma in Qidong risk area, China.World journal of gastroenterology · 2003Article
- Detection of HBV, PCNA and GST-pi in hepatocellular carcinoma and chronic liver diseases.World journal of gastroenterology · 2003Article
- DNA-PKcs subunits in radiosensitization by hyperthermia on hepatocellular carcinoma hepG2 cell line.World journal of gastroenterology · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo confirm if p53 mutation could be a routine predictive marker for the prognosis of hepatocellular carcinoma (HCC) patients.
methodsTwo hundreds and forty-four formalin-fixed paraffin-embedded tumor samples of the patients with HCC receiving liver resection were detected for nuclear accumulation of p53. The percent of P53 immunoreactive tumor cells was scored as 0 to 3+ in P53 positive region (<10% -, 10-30% +, 31-50% ++, >50% +++). Proliferating cell nuclear antigen (PCNA) and some clinicopathological characteristics, including patients' sex, preoperative serum AFP level, tumor size, capsule, vascular invasion (both visual and microscopic), and Edmondson grade were also evaluated.
resultsIn univariate COX harzard regression model analysis, tumor size, capsule status, vascular invasion, and p53 expression were independent factors that were closely related to the overall survival (OS) rates of HCC patients. The survival rates of patients with 3+ for P53 expression were much lower than those with 2+ or + for P53 expression. Only vascular invasion (P<0.05) and capsule (P<0.01) were closely related to the disease-free survival (DFS) of HCC patients. In multivariate analysis, p53 overexpression (RI 0.5456, P<0.01) was the most significant factor associated with the OS rates of patients after HCC resection, while tumor size (RI 0.5209, P<0.01), vascular invasion (RI 0.5271, P<0.01) and capsule (RI-0.8691, P<0.01) were also related to the OS. However, only tumor capsular status was an independent predictive factor (P<0.05) for the DFS. No significant prognostic value was found in PCNA-LI, Edmondson's grade, patients' sex and preoperative serum AFP level.
conclusionAccumulation of p53 expression, as well as tumor size, capsule and vascular invasion, could be valuable markers for predicting the prognosis of HCC patients after resection. The quantitative immunohistochemical scoring for P53 nuclear accumulation might be more valuable for predicting prognosis of patients after HCC resection than the common qualitative analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.